Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Cash from Financing Activities (2016 - 2026)

Champions Oncology (CSBR) has 16 years of Cash from Financing Activities data on record, last reported at $168000.0 in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 29.71% year-over-year to $168000.0; the TTM value through Oct 2025 reached $122000.0, down 6.87%, while the annual FY2025 figure was $170000.0, 132.26% up from the prior year.
  • Cash from Financing Activities reached $168000.0 in Q4 2025 per CSBR's latest filing, up from -$14000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $239000.0 in Q4 2024 and bottomed at -$590000.0 in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $1823.5, with a median of $2000.0 recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: soared 221.43% in 2022, then crashed 568.75% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $121000.0 in 2021, then dropped by 28.93% to $86000.0 in 2022, then soared by 55.81% to $134000.0 in 2023, then surged by 78.36% to $239000.0 in 2024, then decreased by 29.71% to $168000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $168000.0 in Q4 2025, -$14000.0 in Q3 2025, and -$32000.0 in Q2 2025.